It should be noted that unlike solid tumor cells, hematological tumor cells frequently express MHC-II, and thus, the LAG-3-MHC-II interaction still plays a key inhibitory role in CD4+ T cell-mediated control. Here, LAG3 is linked to hematopoietic and lymphoid system neoplasm.